associate sponsors

Havells
HDFC

Sun Pharma Q2 profit more than doubles, beats estimates | Reuters

MUMBAI Sun Pharmaceutical Industries Ltd, India's largest drugmaker, reported on Thursday a quarterly profit that more than doubled from last year, outpacing analysts' expectations, led by robust sales in emerging markets.Net profit for July-September rose to 22.35 billion rupees ($335.8 million) from 10.29 billion rupees a year earlier. Analysts expected an average profit of 16.46 billion rupees, according to Thomson Reuters I/B/E/S.Sales in its largest market, the United States, rose 9 percent, while those in India rose 11 percent. In emerging markets, Sun's sales rose 22 percent, the world's fifth-largest generic drugs maker said in a statement.

"The synergies from the Ranbaxy acquisition are gaining momentum and we are on track to achieve the targeted benefits," Sun's billionaire founder and Managing Director Dilip Shanghvi said in a statement.Sun has earlier said it expects to reap $300 million in synergies by fiscal 2018 from its purchase of rival Ranbaxy Laboratories last year.

($1 = 66.5600 Indian rupees)

(Reporting by Zeba Siddiqui in Mumbai; Editing by Sherry Jacob-Phillips/Keith Weir)

This story has not been edited by Firstpost staff and is generated by auto-feed.


Updated Date: Nov 10, 2016 21:52 PM

Also Watch

Social Media Star: Abhishek Bachchan, Varun Grover reveal how they handle selfies, trolls and broccoli
  • Monday, July 16, 2018 It's a Wrap: Soorma star Diljit Dosanjh and Hockey legend Sandeep Singh in conversation with Parul Sharma
  • Monday, July 16, 2018 Watch: Dalit man in Uttar Pradesh defies decades of prejudice by taking out baraat in Thakur-dominated Nizampur village
  • Monday, July 16, 2018 India's water crisis: After govt apathy, Odisha farmer carves out 3-km canal from hills to tackle scarcity in village
  • Sunday, July 15, 2018 Maurizio Sarri, named as new Chelsea manager, is owner Roman Abramovich's latest gamble in quest for 'perfect football'

Also See